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Abstract
The CCAAT/Enhancer Binding Proteins (C/EBPs) are a family of leucine-zipper transcription factors that regulate
physiological processes such as energy metabolism, inflammation, cell cycle, and the development and differentiation of
several tissues including skin. Recently, a role for C/EBPs in tumor cell proliferation and differentiation has been proposed,
but the incomplete characterization in the literature of multiple translational isoforms of these proteins has made
interpretation of these roles difficult. Therefore, we have carefully reexamined C/EBP isoform expression in human non-
melanoma skin cancers. C/EBPa, C/EBPb, and C/EBPd were analyzed histologically in squamous cell carcinomas (SCC). The
individual isoforms of C/EBPa and C/EBPb were examined by immunofluorescent digital imaging, western blotting and DNA
binding activity (electrophoretic mobility shift analysis). Expression of all C/EBP family proteins was decreased in SCC
tumors. Suppression was greatest for C/EBPa, less for C/EBPb, and least for C/EBPd. Western analyses confirmed that C/EBPa
p42 and p30 isoforms were decreased. For C/EBPb, only the abundant full-length isoform (C/EBPb21, LAP*, 55 kD) was
reduced, whereas the smaller isoforms, C/EBPb22 (LAP, 48 kD) and C/EBPb23 (LIP, 20 kD), which are predominantly
nuclear, were significantly increased in well- and moderately-differentiated SCC (up to 14-fold for C/EBPb23). These
elevations correlated with increases in PCNA, a marker of proliferation. Although C/EBPb displayed increased post-
translational modifications in SCC, phosphorylation of C/EBPb21 (Thr 235) was not altered. C/EBP-specific DNA binding
activity in nuclear and whole-cell extracts of cultured cells and tumors was predominantly attributable to C/EBPb.I n
summary, two short C/EBPb isoforms, C/EBPb22 and C/EBPb23, represent strong candidate markers for epithelial skin
malignancy, due to their preferential expression in carcinoma versus normal skin, and their strong correlation with tumor
proliferation.
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Introduction
C/EBP transcription factors (C/EBPs), a family of six gene
members in which C/EBPa, C/EBPb, and C/EBPd have been
the most intensively studied, were originally identified as regulators
of growth and differentiation in normal tissues [1–3]. More
recently, C/EBPs have received considerable attention as potential
molecular markers that define prognostic risk in cancer; reviewed
in [4–6]. C/EBPa is known to be a tumor suppressor in acute
myelogenous leukemia [reviewed in [7,8]], and is reportedly
down-regulated in human epithelial cancers of the breast [9], lung
[10], liver [11], head and neck [12], endometrium [13], and
squamous cell carcinoma (SCC) of the skin [14]. C/EBPa
expression levels in actinic keratoses and keratoacanthoma
(precancerous skin conditions that can progress to SCC) were
reduced relative to normal epidermis, and fully invasive SCCs
expressed no detectable levels of C/EBPa, indicating a direct
correlation between expression levels of C/EBPa and the severity
of neoplasia [14]. C/EBPb expression, in contrast to C/EBPa,
was reportedly increased in advanced cases of breast, ovarian,
colorectal, renal, and gastric carcinoma [15–21]. However,
interpretation of those reports is complicated by the existence of
three different isoforms of C/EBPb, a major topic of the current
study (see below). C/EBPd gene has been reported to be
methylated in acute myelomoncytic leukemia (AML), cervical,
breast and hepatocellular carcinoma and reduced expression
associated with progression of breast tumors [22]. Other C/EBP
family genes have received relatively less attention, but potential
involvement of dysregulated C/EBPe [23], and C/EBPf/gadd153
[24] in leukemia and melanoma, respectively, has been suggested.
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C/EBPs reflect biological functions in human cancers remains
unresolved, but it appears increasingly clear that changes in the
ratio of C/EBP isoforms could have prognostic significance. C/
EBPa and C/EBPb are intronless genes, each producing a single
mRNA transcript. Different protein isoforms can be produced
from a single C/EBPa or C/EBb transcript via a mechanism of
alternative translation that uses different ATG start codons within
the ribonucleotide sequence [25]. The human C/EBPa transcript
produces two proteins, ,42 kDa and ,30 kDa, whereas the C/
EBPb transcript produces three proteins named LAP*, LAP, and
LIP in mice, or C/EBPb-1, C/EBPb-2, and C/EBPb-3 in
humans, in order of decreasing size [6]. The shortest form can act
as a dominant-negative inhibitor since it contains a DNA-binding
region, yet lacks N-terminal amino acids necessary to transactivate
gene transcription. For this reason, the relative expression levels of
a long and short form, the ‘‘LAP/LIP ratio,’’ was proposed to
participate in regulation of proliferation and differentiation in
normal cells [26,27], and in cancer [28]. This idea now deserves a
revisit as more detailed information has emerged. Linda Sealy
et al. have established that the largest form of C/EBPb observed
in transformed breast cancer cell lines is C/EBPb-2 (LAP),
whereas the full-length C/EBPb-1 (LAP*) is only expressed in
whole tissues in vivo or in primary epithelial cells in vitro [29,30].
Also, elevated expression of C/EBPb-2 in MCF10A normal
human mammary epithelial cells results in transformation, an
epithelial to mesenchymal transition (EMT) and acquisition of an
invasive phenotype, directly linking C/EBPb-2 to severity of
neoplasia [31]. The implications here are two-fold: (i), current
information about C/EBPb-1 is not clear, given many older
reports in which the analyses were performed immunohistologi-
cally and distinction between C/EBPb-1 and C/EBPb-2 was not
recognized; (ii), previous interpretations regarding proteins
extracted from tissues in vivo and detected by western blotting
may need to be reconsidered, in light of newer information.
Murine models of cutaneous carcinogenesis may offer particular
insight because recent reports have indicated important functional
roles for C/EBPa and C/EBPb during tumorigenesis in murine
skin. Mice lacking C/EBPa in the epidermis show normal
proliferation and differentiation but were highly susceptible to
skin tumorigenesis in response to carcinogens. These mice
displayed decreased tumor latency, increased tumor incidence,
multiplicity, growth rate and malignant progression [14,32].
Chemically induced squamous cell carcinomas and also primary
cell lines established from these SCC, showed negligible expression
of C/EBPa as compared with normal epidermis [33]. Also, the
expression levels of C/EBPa or C/EBPb were a direct indicator of
the state of neoplasia, since benign papillomas in mice showed an
intermediate expression level, when compared to normal epider-
mis (highest level) and SCCs (lowest level) in the same study [34].
C/EBPb knockout mice are completely refractory to skin tumor
development in response to chemical carcinogens [35] or UVB
exposure [Anand et al., unpublished results]. A robust increase in
apoptosis accompanied with elevated p53 levels in epidermis has
been suggested as the causative mechanism for this resistance to
tumor formation in C/EBPb null mice [36]. In a similar study, C/
EBPd KO mice showed no difference in the tumor phenotype as
compared to wild type, in response to chemical carcinogen [37].
However, in murine model of mammary tumerigenesis, loss of C/
EBPd resulted in increased mammary tumor multiplicity and
reduced lung metastasis involving the regulation of HIF-1a,
mTOR and FBXW7 [22,38]. The role of C/EBPd as an
inflammatory response gene and also a candidate tumor suppres-
sor gene has been supported by the sensitivity of C/EBPd null
mice to ionizing radiation-induced hematopoietic and intestinal
injury [39].
In this paper, we have re-examined the question of change in
histological expression of the three most abundant C/EBPs (a, b
and d) in human SCC, by looking comprehensively in vivo at
expression of individual protein isoforms and their DNA-binding
ability. Our data confirm an across-the-board downregulation of
C/EBPa but more interestingly, the data show a strong
upregulation of C/EBPb-2 and C/EBPb-3 that correlates with
cellular proliferation in moderately- and well-differentiated SCC
of the skin.
Materials and Methods
Culture of primary keratinocytes and carcinoma cells
Normal human epidermal keratinocytes (NHEKs; Cascade
Biologics, Portland, OR); HEK1 cells (HEK001; from ATCC,
Manassas, VA); and SCC13 cells (gift from Jonathan Garlick,
Tufts University, Boston, MA, [40,41]) were cultured at 37uCi na
humidified CO2 incubator as previously described [42]. Human
prostate carcinoma cells (LNCAP; ATCC) were cultured as
described [43]. cos-7 cells (ATCC) were cultured at 37uCi na5 %
humidified CO2 incubator in DMEM (4 mM L-glutamine, 1.5 g/l
sodium bicarbonate, 4.5 g/l glucose, with10% FBS, 100 units/ml
Penicillin and 100 mg/ml streptomycin). Cells were maintained at
subconfluence (,80–90%) levels, and seeded at a 1:6 to 1:8
dilutions during passaging.
Collection of human tumor specimens
Discarded skin tissues, taken during Moh’s surgery for removal
of SCC tumors diagnosed previously by biopsy, were obtained in a
de-identified manner. This study was approved by the Institutional
Review Board of the Cleveland Clinic. Frozen tissue blocks in
OCT compound (Tissue Tek, Torrance, CA) were screened
histologically, and those that contained usable tumor were stored
at 280uC until further study.
Expression vectors, cell transfection and preparation of
whole-cell and nuclear extracts
Expression vectors (pcDNA3.1) encoding rat C/EBPa and
mouse C/EBPd were kind gifts of David Ron (NYU Medical Ctr,
New York, NY) and James Dewille (Ohio State University,
Columbus, OH), respectively. An expression vector (pCMV6)
encoding human C/EBPb was purchased from Origene (Rock-
ville, MD). An expression vector for human C/EBPb1
(pcDNA3.1hisA) that exclusively expressed the longest form of
C/EBPb due to modification of the ATG for C/EBPb2 was kindly
provided by Linda Sealy (Vanderbilt University, Nashville, TN).
Nuclear extracts from cos-7 cells overexpressing various C/EBPs
(a, b and d) were prepared exactly as described by Schreiber et al.
[44] following transfection of cells in 100 mm dishes using 3 mgo f
expression vector and GenePORTER reagent (Genlantis, San
Diego, CA) according to the manufacturer’s protocol. Whole cell
extracts from cells overexpressing the C/EBPs were prepared by
lysis in urea buffer (7 M urea, 2% IGEPAL, 5% b-mercaptoeth-
anol and protease inhibitor cocktail), followed by 3–5 pulses (4–
6 sec each) of sonication to disrupt membranes, and a 5 min high-
speed microfuge spin to clear the lysates. All procedures were
carried out at 4uC [45].
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expression in human tumors
Cryosections (5 mm) of frozen tumor samples were fixed 5 min
in ice-cold methanol and stained with hematoxylin and eosin by
standard methods. For immunohistochemical detection of C/
EBPs, methanol-fixed cryosections were washed in PBS, and
permeabilized in 0.1% Triton X-100 (Sigma, St Louis, MO) in
PBS for 10 min on ice. Sections were serially incubated in the
following solutions: 3% normal donkey serum, 30 min, room
temperature (RT); primary antisera, overnight, 4uC; PBS rinses,
5 min x 3; Cy3-conjugated donkey anti-rabbit IgG (Jackson
ImmunoResearch, West Grove, PA, 1:1500, for 4 h at RT), PBS
rinse x1; mounting in Vectashield (Vector Lab, Burlingame, CA)
under coverslips. Antisera for C/EBPa, C/EBPb, C/EBPd, E-cad
(all from Santa Cruz Biotechnology, Santa Cruz, CA) and Ki67
(Thermo Fisher, Waltham, MA) were used at 1:50 dilution in PBS.
Semiquantitative analysis of fluorescence intensity in
immunostained sections of human skin tumors
Imaging of fluorescence intensity from immunostained skin
specimens was standardized as follows. Seven different exposures
of a given tumor specimen, and of a normal skin specimen from
the same patient, was digitally captured on an Olympus BX50
fluorescent microscope (Olympus America, Center Valley, PA)
equipped with a OolSNAP-Pro color CCD camera (Media
Cybernetics, Bethesda, MD). Exposure times for each successive
image were lengthened so as to double the amount of light
collected. Pairs of digital images from tumor and normal hair
follicle were compared side-by-side on a computer monitor, and
the two images whose intensities were visually most closely
matched were noted. From the ratio of exposure times of the best-
matched image pair, the relative difference (fold) in C/EBP
protein between tumor and normal was determined. For this
analysis it was assumed that the fluorescent signal is directly
proportional to the amount of C/EBP protein bound by primary
antibody, since no amplification step was employed during
immunostaining. Some examples of images analyzed in this way
are illustrated in Fig. S2.
Western blot analyses
Cells were lysed and for human tumor samples, 30 mm
cryosections (cut perpendicular to the skin surface) were scraped
from the glass slide and pooled, then homogenized, lysed and
sonicated in urea lysis buffer as described [42]. Protein content was
determined by Bradford assay kit (Bio-Rad, Hercules, CA), and
equal amounts were analyzed on western blots using 4–12% Bis-
Tris acrylamide mini gels (Invitrogen, Carlsbad, CA) or 10% Tris-
Glycine gels, as described [42]. The source and dilution of antisera
used here were as follows: C/EBPa, C/EBPb, C/EBPd, Actin and
GAPDH (Santa Cruz,1:5000); PCNA and E-Cadherin (Santa
Cruz, 1:2000); a-Tubulin (Sigma,1:10000), Phospho-C/EBPb
(Cell Signaling, Danvers, MA, 1:1000); and peroxidase-conjugated
goat anti-rabbit IgG (Jackson ImmunoResearch, 1:20,000).
Western blot signals were quantitated using IPLab software
(Scanalytics Inc., Fairfax, VA).
Electrophoretic Mobility Shift Assay (EMSA)
Complementary oligonucleotides (oligos; 29-mer) that spanned
either a well-established C/EBP motif, or a mutant C/EBP motif,
were synthesized (Integrated DNA Technologies, San Diego, CA)
and used for EMSA. The sense and antisense sequences for each
of the oligos are as follows:
C/EBP consensus; (Sense 59 CTAGCATCTGCAGATTGCG-
CAATCTGCAC 39; Antisense 59 TCGAGTGCAGATTGCG-
CAATCTGCAGATG 39).
Mutant C/EBP consensus; (Sense 59 CTAGCATCTGCA-
GAGGTATACCTCTGCAC 39; Antisense 59 TCGAGTGCA-
GAGGTATACCTCTGCAGATG 39). The C/EBP consensus
sequence is shown in bold, and mutant sequences are underlined
[46]. Two pM of duplex oligos, heat denatured and annealed,
were labeled with [a-
32P] dCTP (3,000 Ci/mM, ICN Pharma-
ceuticals) using Klenow polymerase (New England Biolabs,
Ipswich, MA) and purified using Probequant spin columns (GE
Healthcare, Piscataway, NJ). Nuclear extracts (2–3 mg) from cos-7
cells, keratinocytes, or tumor cells were prepared as described [44]
and incubated with 50 fM of labeled oligos in DNA binding buffer
(Hepes pH 7.9, 20 mM, glycerol 10%, KCl 40 mM, NP-40 0.1%,
EDTA 0.5 mM, PMSF 1 mM, DTT 0.5 mM) along with 1 mgo f
non-specific DNA competitor [poly(dG-dC)
. poly (dG-dC)] and
1 ml of filtered FBS for 30 min at room temperature. DNA-protein
complexes were resolved on 4% non-denaturing polyacrylamide
gels in Tris-Glycine-EDTA buffer (Tris 25 mM, Glycine 200 mM
and EDTA 2.25 mM), dried and exposed to X-ray film between
intensifying screens. For supershift experiments, 1 ml of antibody
was added to the mixture and incubated for 15 min prior to
addition of labeled oligos [45].
Statistical analyses
Relative levels of C/EBPs (compared to normal skin) were
quantitated using immunohistological images (three images per
sample) from 10–13 SCC samples and data presented as
mean6SD in Table 1 and Fig. 1B. Protein expression levels
by western blot were quantitated using blots from two independent
experiments and the data presented as average6range in Figs. 2–
4.
Results
Expression of C/EBPa, C/EBPb, and C/EBPd is reduced in
human cutaneous SCC
To obtain qualitative information about expression levels and
intracellular localization of C/EBP transcription factors in skin
cancers in vivo, we used primary antibodies to C/EBPa,C /
EBPb, and C/EBPd to perform immunostaining on frozen SCC
specimens and adjacent normal skin (Fig. 1). Staining patterns for
C/EBPa and C/EBPb in normal epidermis, hair follicles, and
sebaceous glands were consistent with previous reports [47,48] i.e.
C/EBPa and C/EBPb staining was primarily cytoplasmic in the
lower epidermal layers and hair follicle epithelium (Fig. 1A,
‘‘ep’’), but became nuclear in the upper epidermal layers. The
difference between C/EBPa and C/EBPb was that greater
amount of cytoplasmic C/EBPb was also seen in the normal
follicles (Fig. 1A). For C/EBPd, expression was strongly nuclear
throughout all layers of the epidermis (not shown) and in the
follicles (Fig. 1A).
Within SCC tumor nests, the signal intensity for each C/EBP
protein was markedly lower in tumor cells than in normal cells
(Fig. 1A), with some exceptions. To obtain more objective
estimates of changes in C/EBP protein expression in the biopsy
specimens, we devised an ‘‘f-stop’’ technique to quantify changes
in the immunofluorescent signal in digitally-recorded micrographs;
see Methods and Fig. S2. The graphs in Fig. 1B summarize the
results of this enhanced analysis for multiple SCC tumors; data for
the individual tumors are in Table 1. For SCC, C/EBPa was
suppressed in 7/8 specimens, C/EBPb in 6/11 specimens, and C/
EBPd in 5/11 specimens. Thus, in terms of both frequency and
C/EBP Protein Isoforms in Human Skin Carcinoma
PLOS ONE | www.plosone.org 3 November 2014 | Volume 9 | Issue 11 | e112073Figure 1. Expression patterns of C/EBPa, C/EBPb, and C/EBPd in human squamous cell carcinoma (SCC). (A) Frozen skin sections from
patients with SCC were fluorescently immunostained, using antibodies to C/EBPa, C/EBPb, or C/EBPd (as indicated on left) followed by a Cy3-
fluorotagged anti-IgG secondary antibody. Hematoxylin and eosin (H&E) stains were done on parallel sections. Tumor nests (n), and normal hair
follicle epithelium (ep) and cortex (C), are indicated. Inset: Arrowheads indicate well-differentiated squamous cells, expressing high levels of keratins
(red). Scale bars,5 0mm. (B) Quantification of fluorescent staining intensities for the three C/EBP family proteins (a,b and d) in eleven SCC tumors,
relative to normal follicles; mean 6 SD.
doi:10.1371/journal.pone.0112073.g001
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most, C/EBPb less so, and C/EBPd the least.
Both C/EBPa isoforms and CEBPb-1 isoform are
decreased, whereas CEBPb-2 and CEBPb-3 are increased
in malignant SCC cell lines
Because standard immunohistological technique can not
differentiate between isoforms, we used western analysis to further
refine our initial observations of C/EBP protein expression in
SCC, focusing on C/EBPa and C/EBPb. For a preliminary look,
and to confirm the specificity of antibody reagents, we tested
several cell lines that lie along a spectrum of increasingly
malignant behavior. In the order of benign to malignant, the
lines were: (i), NHEK, a normal human epidermal keratinocytes,
(ii), HEK1, a virally transformed human keratinocyte line, (iii),
SCC13, a spontaneously-tranformed squamous cell carcinoma
line, and (iv), LNCAP, a prostate carcinoma line. In these cell
lines, expression profiles of markers of growth-arrest and
differentiation had already been established [see Fig. S1 in ref.
[42]]. Here, western analyses revealed a decrease in both C/EBPa
isoforms (42 kD and 30 kD) in parallel with the hierarchy of
malignant progression (Fig. 2A, B). This finding was consistent
with clinical reports in breast carcinoma [9], human SCC [14] and
experimental cutaneous carcinoma in mice [33,49]. For C/EBPb,
the situation was more complicated. Because previous literature
did not always distinguish between the two large isoforms of C/
EBPb, we took care to confirm the identity of C/EBPb-1 and C/
EBPb-2 on gels by comparing their location on the western blots
with the location of recombinant proteins translated in cos-7 cells.
For calibration purposes, we used: (i), a normal full-length human
C/EBPb sequence that expresses C/EBPb-2 and 23 but not C/
EBPb-1 in the cos-7 cells (Fig. 2C, lanes 2 and 5), and (ii), a
cDNA engineered to express only C/EBPb-1 and not the other
isoforms (lane 4). In the cell lines, the abundant C/EBPb-1 isoform
appeared to decrease with malignant progression (Fig. 2C, lanes
6–8), whereas the two smaller isoforms C/EBPb-2 and C/EBPb-3
were increased 2- to 5-fold (Fig. 2D). These results agree with
others who reported that C/EBPb-1 is expressed in normal
mammary cells and tissues, but not expressed in immortalized cell
lines. These data are also consistent with reports that high C/
EBPb-2 expression can results in transformation, EMT and
acquisition of an invasive phenotype in normal human mammary
epithelial cells [29,31]. We also tested for C/EBPd, but signals on
Western blots were too weak to assess. Low expression levels of C/
EBPd in these cell lines were later confirmed by functional DNA
binding assays (see below).
In human SCC cancers, overall expression of C/EBPa and
C/EBPb is reduced, but expression of two small C/EBPb
isoforms is increased
We next examined human SCC specimens by western blotting.
Obtaining sufficient tumor tissue from skin biopsies was only
possible by pooling multiple thick frozen sections from the largest
tumors, which comprised five invasive SCC. Those specimens
were evaluated by two certified dermatopathologists to determine
the histological tumor grade (Fig. S1). Protein lysates from these
tumors were loaded onto western blots in the order of worsening
neoplasia, using duplicate blots to provide an estimate of
variability (Fig. 3). Three proteins (GAPDH, tubulin and actin)
were used as housekeeping loading controls, instead of only one,
because expression of ‘‘invariant’’ control genes often differs
between skin samples as demonstrated by Minner and Poumay
[50]. Fig. 3A illustrates a typical Western blot for C/EBPa in
normal and carcinoma tissues (only the actin control is shown). C/
EBPa (p42) expression decreased by 60–75% in most of the SCCs,
although less so in the most poorly differentiated tumor (S13). The
C/EBPa p30 isoform was not detected.
For C/EBPb, each isoform behaved differently. The largest
protein, C/EBPb-1, appeared as a thick multi-banded complex
(55–70 kD), indicating a high level of post-translational modifica-
tion (Fig. 3B), as described by Zahnow [6]. The abundance of C/
EBPb-1 was moderately reduced in all SCC (Fig. 3D), although a
more remarkable loss of the highest MW (most post-translationally
modified) forms of C/EBPb-1 was absent in the well-to-
moderately differentiated SCC tumors, S9–S11 (Fig. 3B, dotted
oval). In contrast, the shorter isoforms, C/EBPb-2 and b-3, were
both strongly induced in tumors S9–S11 (Fig. 3B). Although
expressed in low amounts, C/EBPb-2 and C/EBPb-3 differed
Table 1. Relative levels of C/EBPa, C/EBPb and C/EBPd in histological sections of human squamous cell carcinoma.
Protein Expression (% of normal)
Tumor ID# C/EBPa C/EBPb C/EBPd
S1 ND 100 83
S2 53 80 100
S3 ND 43 100
S4 61 100 53
S5 43 55 66
S6 100 66 100
S9 45 100 111
S10 31 100 100
S11 33 42 66
S12 71 100 100
S13 ND 40 64
Mean 6 SD 60626 75626 86620
The relative intensity of immunofluorescent staining (compared to normal skin) for each C/EBP family member was determined semi-quantitatively by making pairwise
visual comparisons between tumor nests and normal hair follicles within the same patient, using the f-stop technique (see Methods and Figure S2). ND, not done.
doi:10.1371/journal.pone.0112073.t001
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normal skin. By densitometry, C/EBPb-2 and C/EBPb-3 were
increased in the well- and moderately-differentiated SCC, but not
in the poorly-differentiated SCC (Fig. 3E). C/EBPb-3 appeared
to offer the greatest signal-to-noise ratio, rising 8- to14-fold in the
moderately-differentiated tumors (Fig. 3E).
The expression patterns of C/EBPb-2 and C/EBPb-3 in
cutaneous SCC correlate with changes in markers of
cellular proliferation and differentiation
To ask whether changes in the short C/EBP isoforms were
correlated with any physiologic markers within tumors, markers of
proliferation (PCNA) and differentiation (E-cadherin) were ana-
lyzed in the SCC by western blot (Fig. 3B, bottom two panels).
PCNA expression levels tracked very closely with expression of the
smallest isoform, C/EBPb-3, such that PCNA and C/EBPb-3
were elevated in the same tumor subset (Fig. 3E and 3F). E-
cadherin did not bear any clear relationship with C/EBPb
expression. However, within SCC tumors as a group, E-cadherin
expression rose as PCNA expression dropped (Fig. 3F), consistent
with a permissive relationship between growth arrest and the onset
of terminal differentiation often seen in squamous epithelia.
Immunohistological analyses of proliferation (Ki67) and differen-
tiation (E-cad) in SCC revealed a similar pattern as described
above (Fig. S3).
The C/EBPb-1 isoform is phosphorylated in SCC, but
phosphorylation does not appear to be differentially
regulated
To begin to examine post-translational modifications of C/
EBPb, we evaluated the phosphorylation state of C/EBPb by
probing blots with a selective antibody against C/EBPb
phosphorylated at threonine-235 (Fig. 4A). Phosphorylation of
the threonine 235 residue in human C/EBPb by Ras-MAPK-
ERK kinase (MEK) signaling pathway results in transcriptional
activation of C/EBPb [6]. Here only one band corresponding to
phosphorylated C/EBPb-1/LAP*, was detected. However, up to
four bands corresponding to various other forms of C/EBPb-1
were apparent in the tumor specimens (Fig. 4B). In normal skin,
only one major form of C/EBPb-1 was seen (Fig. 4B, lanes 1 and
2) and it corresponded to phosphorylated C/EBPb-1. Slower-
migrating forms of C/EBPb were observed in the SCC tumors
and may correspond to acetylation, methylation, or sumoylation,
as reported by others and summarized by Zahnow [6]. The ratio
of phosphorylated C/EBPb-1 to total C/EBPb-1 (defined as those
isoforms located above the dotted line in Fig. 4B) did not change
significantly in SCC relative to normal skin.
Figure 2. C/EBPa and C/EBPb isoforms are differentially expressed in SCC cell lines as compared to normal human keratinocytes.
Western analyses of normal primary keratinocytes (NHEK), and two squamous cell carcinoma cell lines, HEK1 and SCC13. (A) Western blot for C/EBPa,
in the skin cell lines and also in prostate carcinoma cells (LNCAP). GAPDH is a loading control. (B) Densitometric quantification for C/EBPa.( C) Western
blots for C/EBPb. Lanes 2 and 5 (cos b2) contain recombinant human cDNA for C/EBPb overexpressed in cos-7 cells, which translate only LAP and LIP.
Lane 4 (cos b1) contains recombinant human T7 his-tagged C/EBPb-1 plasmid expressed in cos-7 cells. Lanes 1 and 3, extracts from cos-7 cell that
were untransfected or transfected with the empty vector (pVector), respectively. Box, longer exposure of C/EBPb-3. GAPDH, loading control. (D)
Densitometric quantification of each isoform of C/EBPb. Graphs represent the average of two independent Western analyses, with protein levels
normalized to GAPDH and expressed relative to NHEK (dotted line).
doi:10.1371/journal.pone.0112073.g002
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suggest a functional predominance of C/EBPb, relative to
C/EBPa or C/EBPd
To determine which C/EBP isoforms in SCC are capable of
binding to DNA targets, electrophoretic mobility shift analyses
(EMSA) were performed. To validate the techniques, we first
analyzed binding of recombinant C/EBPa, C/EBPb, and C/
EBPd to a DNA oligonucleotide probe harboring a standard C/
EBP consensus sequence (Fig. 5A). Each of the three C/EBPs
bound avidly to DNA, and the protein-DNA complexes were C/
EBP site-specific (i.e., failed to bind to a mutant oligonucleotide),
and C/EBP protein-specific (i.e., were supershifted by preincuba-
tion with anti-C/EBPa, anti-C/EBPb, or anti-C/EBPd antisera,
respectively). Proteins extracted from the nuclei of SCC cell lines
HEK-1 and SCC13 showed mainly C/EBPb-specific binding,
minor binding from C/EBPd, and no binding from C/EBPa
(Fig. 5B).
When studying DNA-binding proteins in whole tumors, one
must use whole-tissue extracts rather than nuclear extracts because
selective extraction of nuclear proteins is impossible (as cells are
disrupted during frozen sectioning). To ask whether C/EBPb
expression profiles in whole cell extracts (WC) vs. nuclear extracts
Figure 3. C/EBPa and C/EBPb expression in human skin SCC. Total protein lysates from normal skin samples (N1, N2), three moderately- or
well-differentiated squamous carcinomas (S9, S10 and S11), and two poorly-differentiated squamous cell carcinomas (S12 and S13) were analyzed on
western blots. Blots for tubulin and actin were done as loading controls for all samples; only actin is shown. (A) Western analyses for C/EBPa.( B)
Western analyses for C/EBPb. The last two lanes are positive controls, consisting of lysates from a prostate cancer cell line (LNCAP) and from cos-7
cells transfected with a native full-length sequence of human C/EBPb (cos/b). Solid box, longer exposure of region within dotted lines. At bottom,
western blots for PCNA and E-cadherin. (C) Densitometric quantification of C/EBPa. Duplicate gels were scanned, and the range shown by the error
bars. (D) Densitometric quantification of C/EBPb21 isoform. (E) Densitometric quantification of C/EBPb22 and C/EBPb23 isoforms. Note that for C/
EBPb-3, the y-axis scale is on the right. (F) Densitometric quantitation of markers for proliferation (PCNA) and differentiation (E-cadherin). All band
intensities were normalized to the average of actin and tubulin (not shown). Error bars, range of duplicate measurements.
doi:10.1371/journal.pone.0112073.g003
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prepared from normal keratinocytes or from HEK1 carcinoma
cells (Fig. 5C). NucX contained C/EBPb-2 and C/EBPb-3
almost exclusively, whereas WC contained mostly C/EBPb-1
(Fig. 5C). When these two lysates were compared by EMSA
(Fig. 5D), the abundance of the protein-DNA complexes that
formed [see bracket with a double asterisk] tended to reflect the
size distribution of C/EBPb isoforms in the extracts, i.e. larger
complexes in WC than in NucX. However, the predominant C/
EBP family member expressed was always C/EBPb, regardless of
whether WC or NucX was examined. We next did DNA binding
studies on total tissue lysates from normal skin and tumor
specimens (Fig. 5E). C/EBPb binding was easily detectable in
all specimens. C/EBPd was only weakly positive, and C/EBPa
was absent. In summary, C/EBPb appears to be the major C/
EBP species present and capable of binding conventional C/EBP
sites on DNA, both in normal skin and in SSC tumors.
Discussion
Nonmelanoma skin cancers (NMSC), comprising basal cell
carcinomas (BCC) and squamous cell carcinomas (SCC), consti-
tute the most common of all human cancers [51]. SCCs, while
representing only 10% of NMSC incidence, are very important
because SCC can readily invade and metastasize. Thus an
important research goal is to recognize features within tissue
biopsies that might identify SCC cancers with the most aggressive
biological behavior. In this manuscript, we have examined the
expression of three members of the C/EBP transcription factor
family that have gained attention as potential prognostic indicators
in cancer. Our finding of decreased expression of C/EBPa in SCC
concurs with previous reports implicating C/EBPa as a tumor
suppressor in myeloid leukemia [8] and cutaneous SCC [14], is
consistent with suggestions that low C/EBPa expression in tumors
contributes to failure of cell cycle arrest [7,9,10,12,33]. For C/
EBPb our data agree with some findings, yet contradict other
aspects of previous clinicopathological studies on C/EBPb
expression in malignancies of various origins [15,18,20,21]. In
agreement, we noted an overall increase in C/EBPb expression in
carcinoma cell lines and in SCC tumors in vivo relative to normal
keratinocytes. However, these increases were entirely due to
elevated amounts of the short isoforms, C/EBPb22 and C/
EBPb23. The full-length isoform C/EBPb21 was actually
slightly decreased. Because most previous studies were not clear
about the exact identity of the large C/EBPb isoforms being
observed, it is not possible to know whether apparent discrepancies
reflect differences between skin and other tissues, or instead reflect
differences in methodologies for protein separation and detection.
In the current study, two additional techniques were employed to
validate our histological findings; namely, western blotting was
calibrated by the use of recombinant C/EBPb isoform standards,
and EMSA was used to determine functional DNA binding
capacity.
Changes in C/EBP expression observed on our western blots
cannot be ascribed to differences in cell populations within
different tissue specimens, because protein lysates were prepared
from frozen biopsy sections with very similar cellular components
by histological examination. Thus, in both the normal skin
specimens and the SCC tumor sections, .90% of the cells were
epithelial (either hair follicles and epidermis, or squamous tumor
cells; see (Fig. S1). Given these equal proportions of normal and
neoplastic epithelial cells, relative changes in C/EBPb isoforms we
observed most likely reflect changes in intracellular C/EBPb
expression, probably at the level of alternative mRNA translation
(see Introduction). However, we cannot rule out a role for
increased transcription of the C/EBPb gene, since studies with
cultured cells show that ER stress (from glucose deprivation or
amino acid deprivation) can induce the expression of human C/
EBPb through unfolded protein response elements in the 39-UTR
of the gene [52,53]. We also cannot rule out the possibility that
post-translational modification of C/EBPb (via upstream signaling
pathways) might affect protein stability and accumulation.
Although changes in phosphorylation appeared to be relatively
minor, other modifications to these proteins were apparent (see
next paragraph).
Changes in differential expression of the C/EBPb isoforms were
among the most interesting findings. C/EBPb-1 (or LAP*)
constituted the vast majority of C/EBPb expressed in the skin,
both normal and SCC, a fact not previously appreciated.
Phosphorylation of this isoform at threonine-235 [54] was not
significantly altered in SCC specimens (Fig. 4A), suggesting that
other modifications such as C/EBPb acetylation, methylation, and
sumoylation as reported in other systems [6] might account for
shifted C/EBPb-1 bands that were apparent in SCC (Fig. 4B). A
recent report by Atwood et al. reported sumoylation of C/EBPb-1
in breast cancer cells as a possible mechanism to circumvent
oncogene induced senescence (OIS) in tumors [55]. Overall, the
changes in C/EBPb-1 were not very impressive, with only a
,50% decrease observed in the SCC along with modest decreases
in post-translational modification (phosphorylation) in well and
Figure 4. C/EBPb-1 is phosphorylated at threonine-235 in
human SCC. Western blots from the same lysates used in Fig. 3
were run and developed with antibodies to either: (A) phospho-C/EBPb
(Thr235), or (B) total C/EBPb. The last lane contains lysates from cos-7
cells transfected with full-length human C/EBPb vector. Dashed lines
indicate the approximate location of recombinant C/EBPb-2 to facilitate
comparisons between the tumor lysates. MW markers in kD are
indicated. Bottom, ratio of phosphorylated-to-total C/EBPb (mean 6
range) from densitometry of two western blot analyses.
doi:10.1371/journal.pone.0112073.g004
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PLOS ONE | www.plosone.org 8 November 2014 | Volume 9 | Issue 11 | e112073Figure 5. C/EBPb, and to a lesser extent C/EBPd, are the predominant C/EBP proteins that bind DNA in human SCC tumors. Protein
lysates from cultured cells (A–D) or from tumors (E) analyzed by EMSA (panels A, B, D and E) or by western blot (panel C). Lysates were incubated with
a
32P-labeled double-stranded DNA probe containing an authentic C/EBP consensus binding sequence (*), or a mutated sequence (m), and the
protein-DNA complexes were run on an acrylamide gel and detected by autoradiography. In some lanes, a supershifting antibody to C/EBPa, C/EBPb,
or C/EBPd, was added to the mixture prior to electrophoresis, as indicated. Lysates for the experiments were: (A) Nuclear extracts from cos-7 cells
transfected with plasmids encoding full-length C/EBPa (cos/a), C/EBPb (cos/b), or C/EBPd (cos/d); (B) Nuclear extracts from normal keratinocytes
(NHEK) or from HEK1 or SCC13 cells; (C) Nuclear extracts (NucX) or whole-cell (WC) extracts from NHEK or HEK1; this panel is an analysis by western
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EBPb-3 (especially C/EBPb-3) were highly induced in SSC
relative to normal skin. Isoform levels correlated directly with
levels of PCNA and therefore may reflect cell division within the
tumors, either directly or indirectly. Overall, these findings suggest
that C/EBPb-2 and C/EBPb-3 represent potential biomarkers of
proliferative potential in cutaneous SCC.
From the literature, C/EBPb appears to be involved in tumor
cell proliferation through regulation of cyclin D1 and its target
genes. Cyclin D1 is often overexpressed in cancers, driving the cell
cycle inappropriately and preventing normal G1 arrest. C/EBPb
may be co-regulatory with cyclin D1, both directly and indirectly
[29,56]. In transient transfection studies, C/EBPb-2 was capable
of binding and activating the cyclin D1 gene promoter; which
would tend to drive the cell cycle [29]. Another mechanism may
involve coregulation of a common set of target genes by C/EBPb
and cyclin D1, as shown by an elegant study in which more than
500 human tumor specimens were examined by gene expression
profiling; the C/EBPb gene was consistently coexpressed with the
same set of genes activated by cyclin D1 [56]. The promoters of
seven of the cyclin D1-responsive genes that were examined in
more detail contained classical C/EBPb binding sites. However,
those promoters were atypical; they were suppressed by wildtype
C/EBPb and activated by a dominant-negative mutant of C/
EBPb (functionally similar to LIP). Thus, C/EBPb21 and/or C/
EBPb22 normally appear to repress cyclin D1 target genes, and
cyclin D1 acts by antagonizing this repressor function. In tumors,
high levels of dominant-negative C/EBPb23 could antagonize the
repression of cyclin D1 target genes by displacing the long C/
EBPb isoforms, activating cell cycle progression.
Our in vivo data in tumors tend to support previous cell culture
and animal experiments demonstrating that C/EBPb23 exerts
preferential effects upon gene transcription that may favor cancer
progression. Zahnow et al. created transgenic mice in which LIP
(C/EBPb-3) was targeted to the mammary gland, leading to
hyperplasia and tumorigenesis [57]. Human breast cancer cells
lose their ability to undergo growth-arrest in response to TGFb;
Gomis et al. showed that forced overexpresion of LIP exacerbated
this loss of TGFb cytostatic response, whereas C/EBPb-2 (LAP)
overexpression restored the response [17]. Positive correlations
between elevated levels of LIP and neoplastic transformation have
been reported in murine mammary epithelial tumors [16] and in
human breast cancers [29]. Such results argue that a high
LIP:LAP ratio is pro-oncogenic whereas a low LIP:LAP ratio
favors normal differentiation. The mechanism of action most often
quoted involves LIP as a dominant negative inhibitor. Because LIP
binds DNA yet lacks a transactivation domain, LIP can displace
other activating isoforms (such as LAP) from sites on DNA and
block transcription of at least some target genes [26,57]. However,
such effects are gene-dependent since LIP actually activates certain
genes in different cellular contexts, as reviewed by Zahnow [6].
Complexities and contradictions abound. For example, C/EBPb-2
(LAP) when overexpressed at high levels using a retroviral vector,
caused neoplastic transformation in human mammary epithelial
cells [30,31], and C/EBPb-3 (LIP) did not cause transformation
and in fact blocked proliferation in that system [31].
C/EBPb-3 is a relatively minor component when compared to
C/EBPb-1, which presents a puzzle when thinking about how C/
EBPb-3 manages to exert such profound effects during malignant
transformation. However, our data suggest that C/EBPb-3 and
C/EBPb-2 may reside in a different geographic and functional
compartment than C/EBPb-1. In whole-cell lysates of HEK1 cells
and NHEK cells, C/EBPb-1 is the major constituent (Fig. 5C).
Yet, C/EBPb-1 is nearly absent in classical nuclear extracts
(nuclear proteins extracted using high salt), where C/EBPb-2 and
C/EBPb-3 are abundant (Fig. 5C). Eaton et al. reported
substantial C/EBPb-1 as well as C/EBPb-2 and C/EBPb-3 in
crude nuclear lysates of normal mammary epithelial cells [29]. In
that case, however, the C/EBPb-1 may have been tightly bound to
nuclear/perinuclear membranes or to chromatin, which were
spun down in the nuclear pellet prior to collection [29]. The fact
that immunostained C/EBPb is consistently observed in cytoplas-
mic/perinuclear locations within basal keratinocytes of normal
epidermis [47], which contain little or no C/EBPb-2 nor C/
EBPb-3, suggests that the abundant C/EBPb-1 isoform resides
preferentially in cytoplasmic/perinuclear membranes in those
locations. In addition, our western data show that C/EBPb-2 and
C/EBPb-3 exist in a more loosely bound state than C/EBPb-1,
being preferentially extractable in high salt buffer. C/EBPb-2 and
C/EBPb-3 may even comprise a majority of the active, DNA-
binding C/EBPs detected within SSC tumor lysates, since in the
EMSA experiments there is a correlation between (i), expression
levels of the individual proteins C/EBPb-2 and C/EBPb-3
(Fig. 3B) and (ii), intensity of C/EBPb-containing DNA/protein
complexes in the EMSA experiments (Fig. 5E); these two
parameters are both high for SCC9 and SCC10, and low for
SCC12 and SCC13.
The idea that C/EBPb-1 and C/EBPb-2 may have different
functional roles is consistent with previous studies. C/EBPb-1 and
-2 were each capable of binding to the cyclin D1 promoter, yet
only C/EBPb-2 could activate a cyclin D1 promoter-reporter
construct in human mammary epithelial cells [29]. Many other
studies showed that C/EBPb-2 is a stronger transactivator than
C/EBPb-1; reviewed in [6]. Distinct functional and binding
properties of C/EBPb-1 may be attributable to the unique N-
terminal region (21 amino acids of C/EBPb-1), that can
specifically bind the SWI-SNF nucleosome remodeling complex
[58], and possibly other proteins as well [6].
The potential clinical utility of C/EBPb-2 and -3 isoforms, as
biomarkers for cancer prognosis, will be difficult to evaluate until a
more sensitive assay for C/EBPb isoform detection in routine skin
biopsy specimens is developed. Our data, however, suggest that
such a developmental effort could be worthwhile. The high
correlation between C/EBPb-3 expression and tumor prolifera-
tion in SCC offers promise. On the other hand, very anaplastic
tumors may lie so far along a pathway to neoplastic degeneration
that normal mechanisms of squamous differentiation no longer
apply. Thus, the poorly-differentiated tumors S12 and S13 showed
no C/EBPb-3 elevation, and showed very low proliferation levels.
In summary, we have demonstrated that levels of C/EBPa,C /
EBPb, and to a lesser extent C/EBPd are decreased in human
SSC. Observed losses of C/EBPa are in accord with the widely
acknowledged tumor suppressor function of C/EBPa, now well-
established in myeloid leukemia and in some solid tumors
including SCCs [4,7,59]. More novel is our finding that C/
EBPb-1 (the most abundant C/EBPb isoform) is also reduced in
skin carcinomas, a fact not previously recognized. Most interest-
ing, however, is our demonstration of a robust and qualitative
induction of C/EBPb-3 which correlates with proliferative activity
and could contribute to gene dysregulation in SSC tumors. Our
blot for C/EBPb;( D) Nuclear extracts or whole-cell extracts from HEK1, analyzed by EMSA; (E) Whole-cell extracts of frozen tissue from SCC specimens
previously analyzed in Fig. 3. The unbound
32P-probe is shown only in panel D.
doi:10.1371/journal.pone.0112073.g005
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constitute most of the functional C/EBP family proteins in SCC.
Combined with experimental evidence from other systems, these
data further strengthen the possibility that C/EBPb-3 (and maybe
also C/EBPb-2) are important players in aberrant gene regulation
in carcinomas, and should be investigated as potentially useful
markers of neoplastic progression in SCC. In other words, the
short C/EBPb proteins should be on the short list of future
biomarker studies.
Supporting Information
Figure S1 Histological grading of the human SCC
tumors analyzed by Western blot and EMSA in Figs 3–
5. Post-fixed frozen skin sections from samples of normal skin, and
five squamous cell carcinomas (SCC9 to SCC13), were stained
with hematoxylin and eosin (H&E). These were the specimens
amongst the specimens in Table 1 that were large enough to
provide sufficient material for Western blot and DNA-binding
analyses. The fields shown here illustrate the following: in normal
skin, the appearance of normal hair follicles (hf) and normal
keratinocytes within a follicular root sheath (arrowheads); in
squamous tumors SCC9 to SCC11, the presence of cells with an
epithelial morphology and eosinophilic keratinizing islands (ker); in
SCC12, unusual clear-cell changes; and in SCC13, nuclear
pleomorphism and a marked stromal response. Scale bar,
100 mm. A histological grade for each SCC specimen, S9 to
S13, was determined by two board-certified dermatopathologists
(Drs. MP and SB). Tumors were scored as well-differentiated
(well), moderately-differentiated (mod), or poorly-differentiated
(poor) using histopathologic criteria such as the presence/absence
of keratinization, nuclear pleomorphism, stromal reaction, etc.
The relative concordance of the two pathologists’ scores is
indicated on each image. S9 was an extensive tumor on the back,
untreated for years. S13 was a metastatic tumor on the face.
(TIF)
Figure S2 Semiquantitative analysis of relative differ-
ences in immunofluorescence, using micrographs of
normal skin and tumor tissue, captured as a continuous
series of timed exposures. Imaging of fluorescence intensity
was standardized as follows. Seven different exposures of a given
tumor specimen, and a normal skin specimen from the same
patient were digitally captured on an Olympus BX50 fluorescent
microscope (Olympus America, Center Valley, PA) equipped with
a CoolSNAP-Pro color CCD camera (Media Cybernetics,
Bethesda, MD). Each exposure time in the series doubled the
amount of collected light. Pairs of digital images from tumor and
normal hair follicles were compared side-by-side on a computer
monitor, and the two images with the most closely matched
intensities were noted. The relative difference in C/EBP protein
between tumor and normal was determined from these exposure
times. This analysis assumes that fluorescent signal is directly
proportional to C/EBP protein bound by primary antibody, since
no amplification step was employed during immunostaining. Two
examples of this analytic approach are shown below. For C/EBPa:
The best match (equal intensities) is for the normal follicle at 2.0 s
and tumor at 6.4 s. From the ratio of exposure times (2.0/6.4), the
tumor is ,0.3 the intensity of normal tissue, or ,3-fold less intense
than the normal hair follicle. For C/EBPb: The best match is the
normal follicle at 2.0 s and the tumor at 3.2 s. (Higher exposure
times were in the saturation range, and therefore less reliable).
From the ratio of exposure times (2.0/3.2), the tumor intensity is
,0.63 or 63% of the normal tissue intensity, a reduction in
intensity of approximately one-third. (Scale bar: 100 mm.)
(TIF)
Figure S3 Immunohistological analyses of differentia-
tion and proliferation in normal skin and SCC tumors.
Methanol fixed frozen sections from normal skin and SCC tumors
(two tumors each) were stained with E-cadherin (E-cad) and Ki67,
markers of differentiation and proliferation, respectively. (A)
Membranous expression of E-cad in cells in epidermis (normal
skin; left panel), in tumor nests from well to moderate
differentiated (middle panel) and poorly differentiated SCCs (right
panel). Note the increase in E-cad expression associated with well
to moderate differentiated state of the SCC. (B) Nuclear
expression of Ki67 in cells of basal layer in epidermis (normal
skin; left panel), in tumor nests from well to moderate
differentiated (middle panel) and poorly differentiated SCCs (right
panel). Note the increase in Ki67 expressing cells in SCCs, a
marker routinely used by dermatopathologists. Scale bar, 50 mM.
(TIF)
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